Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease

BMC Nephrology

Roland Schmitt¹  Hermann Haller¹  Jan Menne¹  Bernhard MW Schmidt¹  Jan Beneke¹  Inga Sörensen-Zender¹ 

[1] Department of Nephrology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover D-30625, Germany

关键词: Adipokine;    Acute kidney injury;    Hemodialysis;    Zinc-alpha2-glycoprotein;   

Others  :  1082894
DOI  :  10.1186/1471-2369-14-145

 received in 2013-05-06, accepted in 2013-07-01,  发布年份 2013

【 摘 要 】

Background

Zinc-alpha2-glycoprotein (AZGP1) is a secreted protein which is synthesized in a variety of cell types. AZGP1 has functionally been implicated in lipid metabolism, the regulation of cell cycling and cancer progression. Previous studies have shown increased circulating AZGP1 levels in patients with chronic kidney disease but AZGP1 has not been investigated in acute kidney injury (AKI). In this study, serum AZGP1 levels were measured in acute and chronic kidney disease to test for a correlation to renal function and other clinical parameters.

Methods

We performed ELISA based measurements of AZGP1 serum levels in 21 patients suffering from grade 3 AKI and in 20 chronic hemodialysis patients. In AKI patients, AZGP1 was first measured before initiation of acute renal replacement therapy and a second measurement was done during renal functional recovery. Sera of healthy blood donors served as controls. The association of AZGP1 with acute and chronic renal dysfunction was analysed, as well as the correlation with clinical parameters, body composition and biochemical variables.

Results

Levels of circulating AZGP1 were significantly elevated in AKI patients. High initial levels of AZGP1 correlated with extra-renal complications but not with parameters of renal function. At follow-up, AZGP1 levels were still increased but now correlated significantly with creatinine, eGFR and urea. Circulating AZGP1 in chronic hemodialysis patients was higher than in AKI patients. An association to parameters of lipid metabolism was not found.

Conclusions

This study illustrates that circulating AZGP1 is not only elevated in chronic hemodialysis patients but also sharply increases during the early phase of AKI. The unexpected association with extra-renal complications during AKI needs further exploration as it might point to unknown biological effects of AZGP1.

【 授权许可】

   
2013 Sörensen-Zender et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F: Zinc alpha 2-glycoprotein: a multidisciplinary protein. Molecular cancer research: MCR 2008, 6(6):892-906.
• [2]Lei G, Brysk H, Arany I, Tyring SK, Srinivasan G, Brysk MM: Characterization of zinc-alpha(2)-glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line. J Cell Biochem 1999, 75(1):160-169.
• [3]Schmitt R, Marlier A, Cantley LG: Zag expression during aging suppresses proliferation after kidney injury. Journal of the American Society of Nephrology: JASN 2008, 19(12):2375-2383.
• [4]Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 2005, 579(1):41-47.
• [5]Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 2004, 101(8):2500-2505.
• [6]Russell ST, Zimmerman TP, Domin BA, Tisdale MJ: Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 2004, 1636(1):59-68.
• [7]Russell ST, Tisdale MJ: Studies on the anti-obesity activity of zinc-alpha2-glycoprotein in the rat. Int J Obes (Lond) 2011, 35(5):658-665.
• [8]Rolli V, Radosavljevic M, Astier V, Macquin C, Castan-Laurell I, Visentin V, Guigne C, Carpene C, Valet P, Gilfillan S, et al.: Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 2007, 581(3):394-400.
• [9]Stejskal D, Karpisek M, Reutova H, Stejskal P, Kotolova H, Kollar P: Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA. Clin Biochem 2008, 41(4–5):313-316.
• [10]Yeung DC, Lam KS, Wang Y, Tso AW, Xu A: Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. J Clin Endocrinol Metab 2009, 94(7):2531-2536.
• [11]Stepan H, Philipp A, Roth I, Kralisch S, Jank A, Schaarschmidt W, Lossner U, Kratzsch J, Bluher M, Stumvoll M, et al.: Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in preeclampsia. J Endocrinol Invest 2012, 35(6):562-565.
• [12]Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, Montanari A, Regolisti G, Fiaccadori E, Cabassi A: Serum adipokine zinc alpha2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metab Clin Exp 2012, 61(1):37-42.
• [13]Ceperuelo-Mallafre V, Escote X, Vilades C, Peraire J, Domingo P, Solano E, Sirvent JJ, Pastor R, Tinahones F, Leal M, et al.: Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. HIV Med 2012, 13(5):297-303.
• [14]Slee AD: Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab 2012, 9(1):36. BioMed Central Full Text
• [15]Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DS, Junior ML, Mafra D: Is zinc-alpha2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Clinica chimica acta; international journal of clinical chemistry 2012, 413(5–6):616-619.
• [16]Philipp A, Kralisch S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M: Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in chronic hemodialysis. Metab Clin Exp 2011, 60(5):669-672.
• [17]Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Velarde GC, Fouque D, Leite M Jr, Mafra D: Zinc-alpha2-Glycoprotein: Is There Association between This New Adipokine and Body Composition in Hemodialysis Patients? Ren Fail 2012, 34(9):1062-1067.
• [18]Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, et al.: Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case–control study. BMJ 2012, 345:e4565.
• [19]David S, Kumpers P, Eisenbach GM, Haller H, Kielstein JT: Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2009, 24(7):2232-2240.
• [20]Levey AS, Stevens LA: Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. American journal of kidney diseases: the official journal of the National Kidney Foundation 2010, 55(4):622-627.
• [21]Ekman R, Johansson BG, Ravnskov U: Renal handling of Zn-alpha2-glycoprotein as compared with that of albumin and the retinol-binding protein. J Clin Invest 1976, 57(4):945-954.
• [22]Tojo A, Kinugasa S: Mechanisms of glomerular albumin filtration and tubular reabsorption. International journal of nephrology 2012, 2012:481520.
• [23]Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116(7):1784-1792.
• [24]Guzik TJ, Mangalat D, Korbut R: Adipocytokines - novel link between inflammation and vascular function? Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 2006, 57(4):505-528.
• [25]Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Ryden M, Arner P, Trayhurn P, Fearon KC, Bing C: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer 2011, 104(3):441-447.
• [26]Russell ST, Tisdale MJ: Role of beta-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-alpha2-glycoprotien (ZAG). Biochim Biophys Acta 2012, 1821(4):590-599.